Fred Hassan - 09 Jan 2026 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Role
Director
Signature
/s/ Fred Hassan
Issuer symbol
COCP
Transactions as of
09 Jan 2026
Net transactions value
$0
Form type
4
Filing time
13 Jan 2026, 16:10:08 UTC
Previous filing
06 Jan 2026
Next filing
12 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hassan Fred Director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON /s/ Fred Hassan 13 Jan 2026 0001110744

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COCP Stock Options (Right to Buy) Award $0 +16,410 $0.000000 16,410 09 Jan 2026 Common Stock 16,410 $1.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.